NCT04976595Unknown4 期
A 24-hour Ambulatory Blood Pressure Monitoring Study in Hypogonadal Men Treated With Natesto Nasal Testosterone Gel
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 入组人数
- 218
- 试验地点
- 30
- 主要终点
- Change From Baseline in 24-Hour Systolic Blood Pressure (SBP) At Day 120
研究概览
简要总结
The purpose of this study is to assess the change in 24-hour ambulatory blood pressure monitoring (ABPM) between baseline (Day 0) and Day 120 following 4 months of testosterone therapy with Natesto.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Voluntarily sign and date the study consent form(s) which have been approved by an Institutional Review Board (IRB). Written consent must be obtained prior to the initiation of any study procedures.
- •Male between 18 and 80 years of age, inclusive, with documented onset of hypogonadism prior to age
- •Serum total testosterone < 300 ng/dL based on 2 consecutive blood samples obtained no greater than 1-4 weeks apart between 6 and 10 AM following an appropriate washout of current androgen replacement therapy if not testosterone naive. Historical values from the past 6 months may be used.
- •Testosterone Therapy naive, OR off any testosterone therapy for at least 4 months OR agree to a 4-month washout of current testosterone therapy prior to entry at Visit
- •Average office blood pressure measurement <140 millimetre of mercury (mmHg) SBP -AND- <90 mmHg DBP.
- •If the participant is on an antihypertensive regimen, he has been on it for at least 4 weeks.
- •Judged to be in good general health as determined by the principal investigator based upon the results of a medical history, physical examination, vital signs, laboratory profile and a 12-lead electrocardiogram (ECG).
排除标准
- •History of significant sensitivity or allergy to androgens, castor oil or product excipients.
- •Clinically significant findings in the pre-study examinations including abnormal breast examination requiring follow-up, an abnormal ECG.
- •Abnormal prostate digital rectal examination (DRE) with palpable nodule(s) or International Prostate Symptom Score (I-PSS) score > 19 points.
- •Body mass index (BMI) ≥ 35 kg/m^
- •Clinically significant abnormal laboratory value, in the opinion of the investigator, in serum chemistry, hematology, or urinalysis including but not limited to:
- •Prostate specific antigen (PSA) > 4 ng/mL
- •Hematocrit < 35% or > 50%
- •Baseline hemoglobin > 16 g/dL
- •Hemoglobin A1C (HbA1C) > 9.0%
- •Estimated glomerular filtration rate (eGFR) <45
- •History of seizures or convulsions, including febrile, alcohol or drug withdrawal seizures.
- •History of any clinically significant illness, infection, or surgical procedure within 4 weeks prior to study drug administration except for diabetes, or renal disease.
- •History of stroke or myocardial infarction within the past 5 years.
- •History of, or current or suspected, prostate or breast cancer.
- •History of diagnosed, severe, untreated, obstructive sleep apnea.
- •History of abuse of alcohol or any drug substance in the opinion of the investigator within the previous 2 years.
- •Currently using tobacco, e-cigarettes or other nicotine containing products.
- •History of nasal disorders such as nasal surgery; nasal trauma resulting in nasal fracture within the previous 6 months or nasal fracture that caused a deviated anterior nasal septum; or sinus surgery or sinus disease.
- •Receipt of any investigational product within 4 weeks of study start.
- •Inability to understand and provide written informed consent for the study.
- •Considered by the investigator or the sponsor-designated physician, for any reason, as an unsuitable candidate to receive Natesto.
- •Participants working night-shifts.
- •Participants performing strenuous manual labor while wearing the ABPM monitor.
- •Participants with chronic atrial fibrillation (interferes with the ability to obtain precise ambulatory recordings).
研究组 & 干预措施
Natesto
Experimental
Participants will administer Natesto, gel, intranasally, three times daily up to Day 120. A multiple-dose dispenser will be used for gel deposition into the nasal cavity.
干预措施: Natesto (Drug)
结局指标
主要结局
Change From Baseline in 24-Hour Systolic Blood Pressure (SBP) At Day 120
时间窗: Baseline (Day 0) and Day 120
The change from baseline (Day 0) in 24-hour SBP after 120 days of Natesto treatment will be assessed.
次要结局
- Change From Baseline in Hourly Average Diastolic Blood Pressure (DBP)(Baseline (Day 0) up to Day 120)
- Change From Baseline in Hourly Average Pulse Pressure(Baseline (Day 0) up to Day 120)
- Change From Baseline in Hourly Average Heart Rate(Baseline (Day 0) up to Day 120)
- Change From Baseline in 24-hour Average Diastolic Blood Pressure (DBP)(Baseline (Day 0) up to Day 120)
- Change From Baseline in 24-hour Average Pulse Pressure(Baseline (Day 0) up to Day 120)
- Change From Baseline in 24-hour Average Heart Rate(Baseline (Day 0) up to Day 120)
- Change From Baseline in Hourly Average Mean Arterial Pressure (MAP)(Baseline (Day 0) up to Day 120)
- Change From Baseline in Hourly Average Systolic Blood Pressure (SBP)(Baseline (Day 0) up to Day 120)
- Percentage of Participants With New Anti-hypertensive Medications(Baseline (Day 0) up to Day 120)
- Percentage of Participants With Dose Increases in Anti-hypertensive Medications(Baseline (Day 0) up to Day 120)
- Change From Baseline in 24-hour Average Mean Arterial Pressure (MAP)(Baseline (Day 0) up to Day 120)
- Change From Baseline in 24-hour Average Systolic Blood Pressure (SBP)(Baseline (Day 0) up to Day 120)
研究者
研究点 (30)
Loading locations...
相似试验
Unknown
1 期
The Use of Ambulatory Blood Pressure Monitors to Assess Angiotensin Converting Enzyme InhibitorsHypertension, Resistant to Conventional TherapyNCT02623036Memorial Health University Medical Center20
已完成
不适用
24-hour Blood Pressure Measurements and Ischemic ConditioningBlood PressureNCT03303404University of Texas at Austin22
已完成
不适用
24-Hour Ambulatory Blood Pressure Monitoring in Community PharmaciesHypertensionNCT03920956Virginia Commonwealth University53
已完成
不适用
Seasonal Variation of Ambulatory Blood PressureHypertensionNCT01119755University of Athens80
已完成
不适用
Ambulatory Blood Pressure Monitoring in HypertensionHypertensionNCT00166634Arkansas Children's Hospital Research Institute126